178 related articles for article (PubMed ID: 15846100)
1. Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations.
Sun SY; Schroeder CP; Yue P; Lotan D; Hong WK; Lotan R
Cancer Biol Ther; 2005 Apr; 4(4):407-13. PubMed ID: 15846100
[TBL] [Abstract][Full Text] [Related]
2. Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells.
Schroeder CP; Kadara H; Lotan D; Woo JK; Lee HY; Hong WK; Lotan R
Cancer Res; 2006 Oct; 66(19):9762-70. PubMed ID: 17018636
[TBL] [Abstract][Full Text] [Related]
3. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
Liu X; Yue P; Zhou Z; Khuri FR; Sun SY
J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9.
Ding H; Han C; Zhu J; Chen CS; D'Ambrosio SM
Int J Cancer; 2005 Feb; 113(5):803-10. PubMed ID: 15499625
[TBL] [Abstract][Full Text] [Related]
6. Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens.
Swamy MV; Cooma I; Reddy BS; Rao CV
Int J Oncol; 2002 Apr; 20(4):753-9. PubMed ID: 11894121
[TBL] [Abstract][Full Text] [Related]
7. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
[TBL] [Abstract][Full Text] [Related]
8. Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
Li N; Li H; Su F; Li J; Ma X; Gong P
Int J Clin Exp Pathol; 2015; 8(8):9010-20. PubMed ID: 26464643
[TBL] [Abstract][Full Text] [Related]
9. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
Liu W; Chen Y; Wang W; Keng P; Finkelstein J; Hu D; Liang L; Guo M; Fenton B; Okunieff P; Ding I
Am J Clin Oncol; 2003 Aug; 26(4):S103-9. PubMed ID: 12902866
[TBL] [Abstract][Full Text] [Related]
10. Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms.
Sun SY; Li W; Yue P; Lippman SM; Hong WK; Lotan R
Cancer Res; 1999 May; 59(10):2493-8. PubMed ID: 10344763
[TBL] [Abstract][Full Text] [Related]
11. Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549.
Fulzele SV; Shaik MS; Chatterjee A; Singh M
J Pharm Pharmacol; 2006 Mar; 58(3):327-36. PubMed ID: 16536899
[TBL] [Abstract][Full Text] [Related]
12. Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines.
Zou CP; Kurie JM; Lotan D; Zou CC; Hong WK; Lotan R
Clin Cancer Res; 1998 May; 4(5):1345-55. PubMed ID: 9607596
[TBL] [Abstract][Full Text] [Related]
13. Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib.
Ramer R; Walther U; Borchert P; Laufer S; Linnebacher M; Hinz B
J Lipid Res; 2013 Nov; 54(11):3116-29. PubMed ID: 23943857
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
[TBL] [Abstract][Full Text] [Related]
15. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
Wang ZL; Fan ZQ; Jiang HD; Qu JM
Carcinogenesis; 2013 Mar; 34(3):638-46. PubMed ID: 23172668
[TBL] [Abstract][Full Text] [Related]
16. Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells.
Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
Cancer Res; 2006 Dec; 66(23):11115-9. PubMed ID: 17145853
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Dandekar DS; Lopez M; Carey RI; Lokeshwar BL
Int J Cancer; 2005 Jun; 115(3):484-92. PubMed ID: 15688368
[TBL] [Abstract][Full Text] [Related]
18. Identification of retinamides that are more potent than N-(4-hydroxyphenyl)retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells.
Sun SY; Yue P; Kelloff GJ; Steele VE; Lippman SM; Hong WK; Lotan R
Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):595-601. PubMed ID: 11401908
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3.
Lai GH; Zhang Z; Sirica AE
Mol Cancer Ther; 2003 Mar; 2(3):265-71. PubMed ID: 12657721
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
